Multi-million oncology deal for Array and Pierre Fabre

16 November 2015

US biotech firm Array BioPharma (Nasdaq: ARRY) and privately-held French drugmaker Pierre Fabre today announced a collaboration to globally develop and commercialize Array's late-stage novel oncology products, binimetinib and encorafenib.

Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, are currently advancing in three, global Phase III trials for melanoma and ovarian cancer. Top-line results from NEMO, a Phase III study of binimetinib in patients with NRAS-mutant melanoma, are anticipated before the end of 2015. Array early this year regained rights to bother compounds from Swiss pharma giant Novartis (NOVN: VX) as a result of the latter’s acquisition of oncology assets from GlaxoSmithKline (The Pharma Letter January 23).

Under the terms of the agreement, Array will receive an upfront payment of $30 million and retains exclusive commercialization rights for binimetinib and encorafenib in the USA, Canada, Japan, Korea and Israel. Pierre Fabre will have exclusive rights to commercialize both products in all other countries, including Europe, Asia and Latin America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK